With 3,871 patients enrolled onto the trial , a median follow-up period of 6.1 years , and 437 RFS events , we achieved an HR of 1.26 ( one sided 95 % UCB , 1.48 ; favoring AC does not allow a conclusion of noninferiority of T with AC ; UCB > 1.3 ) .